Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 223

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas

Open access
Karajannis, M. A., Legault, G., Fisher, M. J., Milla, S. S., Cohen, K. J., Wisoff, J. H., Harter, D. H., Goldberg, J. D., Hochman, T., Merkelson, A., Bloom, M. C., Sievert, A. J., Resnick, A. C., Dhall, G., Jones, D. T. W., Korshunov, A., Pfister, S. M., Eberhart, C. G., Zagzag, D., Allen, J. C. · 2014 · Neuro-Oncology

Abstract

BACKGROUND: Activation of the RAS-RAF-MEK-ERK signaling pathway is thought to be the key driver of pediatric low-grade astrocytoma (PLGA) growth. Sorafenib is a multikinase inhibitor targeting BRAF, VEGFR, PDGFR, and c-kit. This multicenter phase II study was conducted to determine the response rate to sorafenib in patients with recurrent or progressive PLGA. METHODS: Key eligibility criteria included age ≥ 2 years, progressive PLGA evaluable on MRI, and at least one prior chemotherapy treatment. Sorafenib was administered twice daily at 200 mg/m(2)/dose (maximum of 400 mg/dose) in continuous 28-day cycles. MRI, including 3-dimensional volumetric tumor analysis, was performed every 12 weeks. BRAF molecular testing was performed on tumor tissue when available. RESULTS: Eleven patients, including 3 with neurofibromatosis type 1 (NF1), were evaluable for response; 5 tested positive for BRAF duplication. Nine patients (82%) came off trial due to radiological tumor progression after 2 or 3 cycles, including 3 patients with confirmed BRAF duplication. Median time to progression was 2.8 months (95% CI, 2.1-31.0 months). Enrollment was terminated early due to this rapid and unexpectedly high progression rate. Tumor tissue obtained from 4 patients after termination of the study showed viable pilocytic or pilomyxoid astrocytoma. CONCLUSIONS: Sorafenib produced unexpected and unprecedented acceleration of tumor growth in children with PLGA, irrespective of NF1 or tumor BRAF status. In vitro studies with sorafenib indicate that this effect is likely related to paradoxical ERK activation. Close monitoring for early tumor progression should be included in trials of novel agents that modulate signal transduction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/nou059

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 223

Metadata

Authors
Karajannis, M. A., Legault, G., Fisher, M. J., Milla, S. S., Cohen, K. J., Wisoff, J. H., Harter, D. H., Goldberg, J. D., Hochman, T., Merkelson, A., Bloom, M. C., Sievert, A. J., Resnick, A. C., Dhall, G., Jones, D. T. W., Korshunov, A., Pfister, S. M., Eberhart, C. G., Zagzag, D., & Allen, J. C.
Venue
Neuro-Oncology
Published
2014-05-06
Volume
16
Issue
10
Pages
1408-1416
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2171512544
Cited by
223
References
1
FWCI
10.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. https://app.cochat.ai/papers/10.1093/neuonc/nou059
The paper
Karajannis, M. A., Legault, G., Fisher, M. J., Milla, S. S., Cohen, K. J., Wisoff, J. H., Harter, D. H., Goldberg, J. D., Hochman, T., Merkelson, A., Bloom, M. C., Sievert, A. J., Resnick, A. C., Dhall, G., Jones, D. T. W., Korshunov, A., Pfister, S. M., Eberhart, C. G., Zagzag, D., & Allen, J. C. (2014). Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/nou059

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.